<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Franklin D Lowy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1426839635"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Issues related to the treatment of bacteremia (in the absence of endocarditis) in adults caused by methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) will be reviewed here.</p><p>General issues related to the clinical approach to patients with <em>S. aureus</em> bacteremia are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults"</a>.)</p><p>Issues related to treatment of MRSA endocarditis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis", section on 'Methicillin resistant'</a> and  <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">"Antimicrobial therapy of prosthetic valve endocarditis", section on 'Staphylococci'</a>.)</p><p>Other issues related to MRSA are discussed further separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3157.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3153.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3152.html" rel="external">"Virulence determinants of community-acquired methicillin-resistant Staphylococcus aureus"</a>.)</p><p></p><p>Issues related to treatment of <em>S. aureus</em> bacteremia caused by vancomycin-intermediate and vancomycin-resistant isolates (<a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> minimum inhibitory concentration ≥4) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3165.html" rel="external">"Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin", section on 'Infection due to VISA or VRSA'</a>.)</p><p class="headingAnchor" id="H1758022357"><span class="h1">CLINICAL APPROACH</span><span class="headingEndMark"> — </span>General issues related to the clinical approach to the treatment of MRSA bacteremia, including history and physical examination, infectious disease consultation, echocardiography, imaging, and source control, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Clinical approach'</a>.)</p><p class="headingAnchor" id="H2685934712"><span class="h1">INTERPRETING ANTIBIOTIC SUSCEPTIBILITY DATA</span></p><p class="headingAnchor" id="H2518415152"><span class="h2">MIC breakpoints</span><span class="headingEndMark"> — </span>Methicillin resistance in <em>S. aureus</em> is defined as an <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> minimum inhibitory concentration (MIC) of ≥4 mcg/mL [<a href="#rid1">1</a>]. </p><p><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> breakpoints for <em>S. aureus</em> (preferably determined by E-tests) set by the United States Clinical and Laboratory Standards Institute (CLSI) are as follows [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Susceptible = MIC ≤2 mcg/mL </p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate = MIC 4 to 8 mcg/mL</p><p class="bulletIndent1"><span class="glyph">●</span>Resistant = MIC ≥16 mcg/mL  </p><p></p><p><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> breakpoints for <em>S. aureus</em> set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>Susceptible = MIC ≤2 mg/L </p><p class="bulletIndent1"><span class="glyph">●</span>Resistant = MIC &gt;2 mg/L</p><p></p><p class="headingAnchor" id="H1448889970"><span class="h2">Outcome data</span><span class="headingEndMark"> — </span>Data regarding the impact of antibiotic susceptibility on response to treatment are conflicting, and other factors (apart from MIC) may influence clinical outcome. For these reasons, clinical factors (including symptomatic improvement and timeframe for clearance of bacteremia) are the most important indicators of response to antimicrobial therapy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome data based on MIC are conflicting</strong> − Some studies suggest a worse clinical outcome associated with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> therapy for infection due to MRSA with vancomycin MIC ≥2 mcg/mL [<a href="#rid2">2-8</a>], while others do not [<a href="#rid9">9-12</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2012 meta-analysis including 22 studies noted increased mortality among patients with MRSA bacteremia (<a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> MIC ≥2 mcg/mL by E-test) treated with vancomycin (odds ratio [OR] 1.7, 95% CI 1.3-2.2); increased mortality was not observed in cases with vancomycin MIC ≤1.5 mcg/mL [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent2">Similarly, in a 2016 retrospective study including 170 patients with MRSA bacteremia (<a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> MICs 1.5 to 2 mcg/mL), treatment with vancomycin was associated with a higher rate of treatment failure (24 versus 11 percent) and a higher rate of renal complications (23 versus 9 percent) than <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, a 2014 meta-analysis including 38 studies and more than 8200 episodes of <em>S. aureus </em>bacteremia found no difference in mortality between patients whose isolate had high <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> MIC (≥1.5 mg/L) and those whose isolate had low vancomycin MIC (&lt;1.5 mg/L) [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent2">Similarly, a 2016 prospective study including 429 patients with<em> S. aureus</em> bacteremia noted that there was no association between <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> MIC and 30- or 90-day mortality [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors (apart from MIC) may influence clinical outcome</strong> – There may be other factors (apart from <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> MIC) that contribute to clinical outcome; in one study including 532 patients with <em>S. aureus b</em>acteremia, those with infection due to strains with vancomycin MIC &gt;1.5 mcg/mL (by E-test) had poorer outcomes than those infected with strains with vancomycin MIC ≤1.5 mcg/mL [<a href="#rid7">7</a>]; the outcome was independent of the methicillin susceptibility and whether the patients were treated with vancomycin or a beta-lactam.</p><p></p><p class="bulletIndent1">In addition, clinical failure has been observed in patients without evidence of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> resistance [<a href="#rid14">14</a>]; some of these failures have occurred in patients with heteroresistant infection (in which subpopulations of organisms have higher vancomycin MICs), although it is uncertain whether heteroresistance is a cause of vancomycin treatment failure [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Heteroresistance'</a>.)</p><p></p><p class="headingAnchor" id="H108561660"><span class="h1">ANTIMICROBIAL THERAPY</span><span class="headingEndMark"> — </span>Treatment of MRSA bacteremia consists of prompt source control (such as removal of infected vascular catheters and/or drainage of purulent collections if present) as well as initiation of appropriate antimicrobial therapy. </p><p class="headingAnchor" id="H3758612337"><span class="h2">Initial treatment</span><span class="headingEndMark"> — </span>Initial treatment of MRSA bacteremia consists of monotherapy with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>; <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> is an acceptable alternative agent. <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">Ceftobiprole</a> is also a potential alternative agent; thus far it is not available in the United States. (See <a class="local">'Treatment regimens'</a> below and <a class="local">'Agents warranting further study'</a> below.) </p><p>Issues related to empiric treatment of <em>S. aureus</em> bacteremia (prior to availability of susceptibility data) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Empiric antibiotic therapy'</a>.)</p><p class="headingAnchor" id="H2273043728"><span class="h2">Tailor treatment to clinical circumstances</span><span class="headingEndMark"> — </span>Following initiation of antibiotic treatment for MRSA bacteremia, blood cultures should be repeated to document clearance of bacteremia. Persistent bacteremia (ie, 48 to 72 hours after initiation of treatment) has been associated with increased morbidity and mortality [<a href="#rid16">16-18</a>]. Failure to clear bacteremia within 48 to 72 hours after initiation of therapy should prompt further evaluation. (See <a class="local">'Unfavorable response to initial treatment'</a> below.)</p><p class="headingAnchor" id="H3697252455"><span class="h3">Favorable response to initial treatment</span><span class="headingEndMark"> — </span>A favorable clinical response to initial treatment includes clearance of bacteremia within 48 to 72 hours, resolution of fever and improvement in clinical manifestations. </p><p>The optimal approach to treatment of patients with a favorable clinical response is uncertain; thus far, monotherapy (with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>) remains standard of care [<a href="#rid19">19</a>]. However, further study of combination therapy is needed; some investigators have proposed combination therapy for patients with no clear source of bacteremia and risk factors for poor outcome (including critical illness, age &gt;65 years, renal disease, vertebral spine infection, injection drug use, and/or prior vancomycin therapy) [<a href="#rid20">20</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monotherapy</strong> − For patients with MRSA bacteremia who respond clinically to initial treatment with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, we continue treatment with vancomycin; <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> is an acceptable alternative regimen  (<a class="graphic graphic_table graphicRef114038" href="/z/d/graphic/114038.html" rel="external">table 1</a>) [<a href="#rid19">19</a>]. <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">Ceftobiprole</a> is also a potential alternative agent; thus far it is not available in the United States. (See <a class="local">'Vancomycin'</a> below and <a class="local">'Daptomycin'</a> below and <a class="local">'Agents warranting further study'</a> below.)</p><p></p><p class="bulletIndent1">In areas where teicoplanin is available, some use it as the drug of choice for initial therapy of <em>S. aureus</em> bacteremia, while others favor its use for patients intolerant to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid21">21</a>]. (See <a class="local">'Teicoplanin (in areas where available)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy</strong> – Data on use of combination therapy are discussed further below. (See <a class="local">'Combination therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H1398633313"><span class="h3">Unfavorable response to initial treatment</span><span class="headingEndMark"> — </span>Patients with unfavorable clinical response to initial treatment (persistent bacteremia beyond 48 to 72 hours, persistent fever, and lack of improvement in clinical manifestations) warrant further evaluation and antibiotic adjustment as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical evaluation </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should undergo evaluation for occult focus of infection that may require drainage. The approach to imaging should be tailored to findings on history and physical examination. Persistent foci of infection (such as a deep-seated bone infection, abscess, retained prosthetic device, or endovascular source of infection) should be eliminated if feasible [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotic susceptibility results (on the original isolate as well as the breakthrough isolate) should be reviewed carefully for susceptibility to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> as well as alternative agents. Repeated isolation of <em>S. aureus</em> from normally sterile sites despite seemingly appropriate antibiotic therapy should prompt suspicion for emergence of an <em>S. aureus</em> isolate with reduced vancomycin susceptibility, even if the MIC of the original isolate was within the susceptible range [<a href="#rid2">2,23-25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic adjustment</strong> − For patients with persistent bacteremia (beyond 48 to 72 hours) in the absence of a removable focus of infection, antibiotic failure should be suspected and antibiotic adjustment is warranted [<a href="#rid16">16,19,26-28</a>]. </p><p></p><p class="bulletIndent1">The optimal antibiotic approach is uncertain; options include switching from <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> monotherapy or switching to combination therapy: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Switch from </strong><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a><strong> to </strong><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a><strong> monotherapy</strong> – For patients with a clear source of bacteremia (such as skin/soft tissue infection) in the absence of the above risk factors, we favor switching to daptomycin monotherapy [<a href="#rid19">19</a>]. (See <a class="local">'Daptomycin'</a> below.)</p><p></p><p class="bulletIndent2">Caution is required when treating <em>S. aureus </em>infection with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> in the setting of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> failure; infrequently, <em>S. aureus</em> nonsusceptibility to daptomycin has been observed when bacteremia has persisted in spite of vancomycin therapy [<a href="#rid29">29</a>]. In addition, breakthrough staphylococcal bacteremia in patients treated with daptomycin may reflect emergence of daptomycin nonsusceptibility; this possibility should be evaluated by performing susceptibility studies on breakthrough isolates.</p><p></p><p class="bulletIndent2">For patients with bacteremia attributable to a pneumonia source, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should not be used; the approach to treatment of MRSA pneumonia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Methicillin-resistant S. aureus'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Switch from monotherapy to combination therapy</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a clear source of bacteremia (such as skin/soft tissue infection) in the absence of the above risk factors who were initially treated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> (in the setting of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> intolerance), we favor switching to combination therapy. Cultures should be repeated; if a new isolate is identified, daptomycin susceptibility should be re-evaluated. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with no clear source of bacteremia and increased risk for poor outcome (including critical illness, age &gt;65 years, renal disease, vertebral spine infection, injection drug use, and/or prior <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> therapy) [<a href="#rid18">18,20,30</a>], we favor switching from vancomycin monotherapy to combination therapy [<a href="#rid20">20</a>]. (See <a class="local">'Combination therapy'</a> below.)</p><p></p><p class="bulletIndent2">Among the combination regimens, we favor <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> plus <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>, if supported by susceptibility data. In such cases, we administer combination therapy until bacteremia has cleared with resolution of fever and clinical improvement, then complete treatment with monotherapy (daptomycin or ceftaroline, depending on clinical circumstances). (See <a class="local">'Combination therapy'</a> below.) </p><p></p><p class="headingAnchor" id="H809989535"><span class="h2">Duration of treatment</span><span class="headingEndMark"> — </span>The duration of treatment f<em>or S. aureus</em> bacteremia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Completing antibiotic therapy'</a>.)</p><p class="headingAnchor" id="H1666912120"><span class="h1">TREATMENT REGIMENS</span></p><p class="headingAnchor" id="H344059092"><span class="h2">Monotherapy</span></p><p class="headingAnchor" id="H2204430327"><span class="h3">Preferred agents</span></p><p class="headingAnchor" id="H1666912127"><span class="h4">Vancomycin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> is a bactericidal glycopeptide antibiotic that inhibits cell wall synthesis; in vitro, it kills staphylococci more slowly than beta-lactam antibiotics and is inferior to beta-lactams for treatment of methicillin-susceptible <em>S. aureus</em> bacteremia [<a href="#rid4">4,31-35</a>].</p><p><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> is the antibiotic agent for which there is the greatest cumulative clinical experience for treatment of MRSA bacteremia [<a href="#rid19">19</a>]. The mortality rate associated with vancomycin monotherapy for treatment of <em>S. aureus </em>bacteremia is 20 to 25 percent [<a href="#rid30">30</a>].</p><p>Dosing is discussed separately; monitoring is necessary due to risk of nephrotoxicity. (See  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults"</a>.)</p><p class="headingAnchor" id="H1666912353"><span class="h4">Daptomycin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is a bactericidal cyclic lipopeptide antibiotic with concentration-dependent activity [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/129183.html" rel="external">"Daptomycin: An overview"</a>.)</p><p>Dosing for treatment of bacteremia (as approved by the US Food and Drug Administration [FDA]) consists of 6 mg/kg intravenously (IV) once daily; however, we favor higher dosing of 8 to 10 mg/kg IV once daily since <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> exhibits concentration-dependent killing [<a href="#rid38">38,39</a>].</p><p>The <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> minimum inhibitory concentration may increase during therapy and may be influenced by prior exposure to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid40">40</a>]. Therefore, daptomycin susceptibility testing must be performed prior to therapy and repeated in the event of positive cultures obtained during therapy, particularly if prolonged therapy is administered and/or there is microbiologic evidence of persistent infection during therapy [<a href="#rid19">19</a>].</p><p>Adverse effects associated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> include myopathy, peripheral neuropathy, and eosinophilic pneumonia [<a href="#rid41">41</a>]. Serial measurements of serum creatine kinase should be monitored at least weekly, and daptomycin should be discontinued in patients with symptomatic myopathy and creatine phosphokinase (CPK) ≥5 times the upper limit of normal (ULN) or in asymptomatic patients with CPK ≥10 times the ULN. (See  <a class="medical medical_review" href="/z/d/html/129183.html" rel="external">"Daptomycin: An overview"</a>.)</p><p>Efficacy data for <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> include: </p><p class="bulletIndent1"><span class="glyph">●</span>A 2006 randomized trial including 246 patients with <em>S. aureus</em> bacteremia (89 patients with MRSA bacteremia) in which <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> was demonstrated to be noninferior to an antistaphylococcal penicillin or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> plus low-dose <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> for treatment of <em>S. aureus</em> bacteremia [<a href="#rid40">40</a>]. At the time of the trial, the comparator regimen was standard of care; however, synergistic aminoglycosides are no longer routinely used for treatment of <em>S. aureus</em> infection given their association with renal dysfunction. A successful outcome was observed for 44 percent of patients who received daptomycin and 42 percent of patients who received antistaphylococcal penicillin or vancomycin plus low-dose gentamicin (absolute difference 2.4 percent, 95% CI -10.2 to 15.1 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2016 retrospective cohort study including 262 cases of MRSA bacteremia between 2010 to 2015 in which those who received <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> had a lower mortality rate (6.1 versus 15.3 percent) and a lower clinical failure rate (composite endpoint including mortality, bacteremia ≥7 days, or a change in antibiotic regimen due to persistent or worsening signs or symptoms; 29 versus 45 percent) than those who received <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2021 retrospective study including more than 7400 patients with MRSA bacteremia in which 30-day survival was superior among patients switched from <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> within three days of treatment onset (hazard ratio 0.48, 95% CI 0.25-0.92); the survival advantage did not persist beyond this early window [<a href="#rid43">43</a>].</p><p></p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> should not be used for treatment of MRSA bacteremia associated with pneumonia. (See  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Methicillin-resistant S. aureus'</a>.)</p><p class="headingAnchor" id="H2046100574"><span class="h4">Teicoplanin (in areas where available)</span><span class="headingEndMark"> — </span>Teicoplanin is a bacteriostatic glycopeptide with similar spectrum of activity and efficacy as <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid44">44,45</a>]. It has a longer half-life than vancomycin and can be administered once daily with more rapid infusion rates than vancomycin. It can also be given intramuscularly.</p><p>Teicoplanin tends to be better tolerated than <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>. In one meta-analysis including 1276 patients, the efficacy of teicoplanin and vancomycin was similar, but there were fewer episodes of vancomycin infusion reaction and other adverse events in patients treated with teicoplanin (14 versus 21 percent) [<a href="#rid44">44</a>]. Another meta-analysis including 24 studies and 2610 patients noted a lower risk of nephrotoxicity with teicoplanin than with vancomycin (risk ratio 0.51, 95% CI 0.30-0.88) [<a href="#rid21">21</a>].</p><p>Teicoplanin is not available in the United States. In areas where it is available, some favor its use for patients with intolerance to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, while others use it as the drug of choice for initial therapy of gram-positive pathogens [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H943808084"><span class="h3">Agents warranting further study</span><span class="headingEndMark"> — </span>Antimicrobial agents warranting further investigation for treatment of MRSA bacteremia are summarized below. Antibiotic susceptibility should be determined prior to use. Agents that are <strong>not</strong> appropriate for monotherapy of MRSA bacteremia include fluoroquinolones, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX), <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">tigecycline</a>, and <a class="drug drug_general" data-topicid="9515" href="/z/d/drug information/9515.html" rel="external">quinupristin-dalfopristin</a> [<a href="#rid47">47-51</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cephalosporins</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">Ceftaroline</a> – Ceftaroline is a bactericidal fifth-generation cephalosporin; it is administered as a prodrug whose active metabolite has activity against MRSA and vancomycin-intermediate <em>S. aureus </em>(VISA) as well as some gram-negative pathogens [<a href="#rid52">52</a>]. Ceftaroline has in vitro activity against staphylococci with reduced susceptibility to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent2">Thus far <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> is approved by the FDA for community-acquired bacterial pneumonia with concurrent bacteremia but not for bacteremia in other contexts. </p><p></p><p class="bulletIndent2">Data supporting use of <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> for treatment of MRSA bacteremia are limited [<a href="#rid54">54-57</a>]. In one retrospective study including 270 patients with MRSA bacteremia treated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> or ceftaroline, no difference in 30-day mortality was observed [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent2">For treatment of bacteremia, we favor administration of <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> every eight hours  (<a class="graphic graphic_table graphicRef114038" href="/z/d/graphic/114038.html" rel="external">table 1</a>), which is more frequent than dosing for other indications such as pneumonia or skin and skin structure infections [<a href="#rid57">57,59</a>]. </p><p></p><p class="bulletIndent2">Prolonged use of <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> has been associated with neutropenia; monitoring of hematologic parameters is warranted for patients taking ceftaroline &gt;7 days [<a href="#rid60">60</a>]. In addition, ceftaroline has been associated with encephalopathy in patients with severe kidney impairment [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">Ceftobiprole</a> – Ceftobiprole is a bactericidal fifth-generation cephalosporin with activity against MRSA and MSSA; it is available outside the United States, including in Canada and the European Union. </p><p></p><p class="bulletIndent2">Among patients with complicated <em>S. aureus</em> bacteremia, <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">ceftobiprole</a> has been observed to be noninferior to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>. In a trial including 387 patients with <em>S. aureus</em> bacteremia (of whom 75 percent had methicillin-susceptible infection), patients were randomly assigned to treatment with ceftobiprole or daptomycin [<a href="#rid62">62</a>]. The most common conditions were soft tissue infection (237 patients) and osteoarticular infection (67 patients); the median treatment duration was 21 days (range 21 to 24 days). The rate of treatment success (survival, symptom improvement, <em>S. aureus</em> bloodstream clearance, absence of new bacteremia-related complications, and no use of other potentially effective antibiotics) was comparable between the groups (69.8 versus 68.7 percent; adjusted difference, 2.0 percentage points; 95% CI −7.1 to 11.1), as was the frequency of serious adverse events (18.8 versus 22.7 percent, respectively). However, the trial was not powered for subgroup evaluation; further study of ceftobiprole in patients with MRSA bacteremia is needed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipoglycopeptides</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">Telavancin</a> − Telavancin is a bactericidal semisynthetic lipoglycopeptide that inhibits cell wall synthesis and disrupts cell membrane permeability [<a href="#rid63">63-67</a>]. It has a half-life of seven to nine hours, permitting once-daily dosing. Telavancin should be avoided in patients at risk for nephrotoxicity. Telavancin has a higher rate of toxicity than <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (including taste disturbance, nausea, vomiting, and renal dysfunction) and has been associated with teratogenicity. </p><p></p><p class="bulletIndent2">Data on <a class="drug drug_general" data-topicid="9535" href="/z/d/drug information/9535.html" rel="external">telavancin</a> for treatment of bacteremia are limited [<a href="#rid68">68</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">Dalbavancin</a><strong> and </strong><a class="drug drug_general" data-topicid="96543" href="/z/d/drug information/96543.html" rel="external">oritavancin</a> − Dalbavancin and oritavancin are long-acting lipoglycopeptides; data on these agents for treatment of MRSA bacteremia are limited [<a href="#rid69">69</a>]. Two studies reported success using dalbavancin as follow-up treatment for serious staphylococcal infections among people who inject drugs and for patients with bacteremia [<a href="#rid70">70,71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a><strong> and </strong><a class="drug drug_general" data-topicid="96001" href="/z/d/drug information/96001.html" rel="external">tedizolid</a> – Linezolid and tedizolid are bacteriostatic oxazolidinones that inhibit initiation of protein synthesis at the 50S ribosome [<a href="#rid72">72,73</a>]. This drug class may have enhanced efficacy against strains producing toxins such as Panton-Valentine leukocidin, alpha-hemolysin, and toxic shock syndrome toxin 1 [<a href="#rid74">74-76</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> has excellent tissue distribution and may be administered parenterally or orally  (<a class="graphic graphic_table graphicRef114038" href="/z/d/graphic/114038.html" rel="external">table 1</a>). In a randomized trial including 95 adults with MRSA bacteremia, linezolid and <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> had equivalent clinical cure rates (56 and 50 percent, respectively) [<a href="#rid77">77</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> resistance has been observed among MRSA isolates; the mechanism appears to be via the bacterial <em>cfr</em> gene, which resides in a potentially mobile genetic element [<a href="#rid78">78</a>]. Clinical outbreaks of linezolid-resistant <em>S. aureus</em> have been described; reduction of linezolid use and infection control measures were associated with termination of the outbreaks [<a href="#rid79">79,80</a>].</p><p></p><p class="bulletIndent1">Safety concerns limit the extended use of <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>. Adverse effects include thrombocytopenia, anemia, lactic acidosis, peripheral neuropathy, serotonin toxicity, and ocular toxicity [<a href="#rid81">81-83</a>]. (See  <a class="medical medical_review" href="/z/d/html/129184.html" rel="external">"Linezolid and tedizolid (oxazolidinones): An overview"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> can reversibly inhibit monoamine oxidase; when administered with serotonergic agents (particularly selective serotonin reuptake inhibitors), it can induce the serotonin syndrome [<a href="#rid84">84,85</a>]. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational agents</strong> − Bacteriophages and endolysins are being studied for the treatment of serious MRSA infections [<a href="#rid86">86</a>]. In one proof of concept study, including 43 patients with<em> </em>MRSA<em> </em>bacteremia/endocarditis, patients were randomly assigned to receive standard of care (SOC) or SOC plus a single infusion of exebacase (an antistaphylococcal lysin), the 14-day clinical response rate was higher in the exebacase group (74 versus 31 percent) [<a href="#rid87">87</a>]. </p><p></p><p class="headingAnchor" id="H1860303752"><span class="h2">Combination therapy</span><span class="headingEndMark"> — </span>The optimal approach to use of combination antibiotic therapy for treatment of MRSA bacteremia is uncertain; potential circumstances in which such treatment may be appropriate are discussed above [<a href="#rid20">20</a>]. (See <a class="local">'Unfavorable response to initial treatment'</a> above.)</p><p class="headingAnchor" id="H1525520204"><span class="h3">Daptomycin and ceftaroline</span><span class="headingEndMark"> — </span>Combination therapy with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> plus <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> may be a useful regimen for treatment of MRSA bacteremia; further study is needed.</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study including 58 patients treated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> (mean dose 8.2 mg/kg IV every 24 hours) plus <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> (600 mg IV every 8 hours) and 113 matched controls (treated with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>), those treated with combination therapy had a lower 30-day mortality (8.3 versus 14.2 percent) [<a href="#rid88">88</a>]. In addition, among 63 patients who received initial vancomycin treatment but required salvage therapy in the setting of endovascular infection, there was a trend toward improved survival among those who switched within 72 hours of the index culture. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized open-label trial including 40 patients treated with either <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> (6 to 8 mg/kg IV every 24 hours) plus <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> (600 mg IV every 8 hours) or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, the in-hospital mortality rates were 0 versus 26 percent, respectively, leading to early study termination for ethics [<a href="#rid89">89</a>]. </p><p></p><p>For combination therapy regimens, we administer <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> dosed at 8 to 10 mg/kg (rather than 6 mg/kg) intravenously daily.</p><p class="headingAnchor" id="H3293850068"><span class="h3">Other regimens</span><span class="headingEndMark"> — </span>Combination regimens warranting further investigation for treatment of MRSA bacteremia are summarized below.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a><strong> plus a beta-lactam</strong> – Combination therapy with daptomycin plus a beta-lactam may be a useful regimen for treatment of MRSA bacteremia if administered early in the course of bacteremia; further study is needed.</p><p></p><p class="bulletIndent1">In a retrospective study including 229 patients treated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> with or without beta-lactam (including cephalosporins, <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>), those treated with combination therapy had a reduced odds of clinical failure (adjusted odds ratio 0.39, 95% CI 0.18-0.85) [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a><strong> plus a hydrophilic beta-lactam</strong> – Combination therapy with vancomycin plus a hydrophilic beta-lactam (<a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>, <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a>) may be a useful regimen for treatment of MRSA bacteremia [<a href="#rid91">91-93</a>]; further study is needed. However, available data suggest that combination therapy with vancomycin plus a hydrophobic beta-lactam (such as <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, flucloxacillin, or <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">cloxacillin</a>) is precluded by increased risk of nephrotoxicity [<a href="#rid20">20,94</a>]. </p><p></p><p class="bulletIndent1">In a randomized trial including more than 300 patients with MRSA bacteremia, addition of a beta-lactam (flucloxacillin, <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">cloxacillin</a>, or <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>; most received flucloxacillin or cloxacillin) to standard antibiotic therapy (intravenous <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>; most received vancomycin) was not associated with improvement in the primary composite end point of 90-day mortality, persistent bacteremia at day 5, relapse, or treatment failure (absolute difference -4.2 percent, 95% CI -14.3 to 6.0 percent) [<a href="#rid94">94</a>]. However, the all-cause mortality in the vancomycin arm was 11 percent (lower than the mortality rate of 20 to 25 percent generally accepted in the literature); in addition, only 4.3 percent had confirmed endocarditis but 38 percent had skin or catheter sources of bacteremia, suggesting that the study population represented a lower risk group without need for combination therapy [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Nephrotoxicity occurred more frequently among patients treated with combination therapy (23 versus 6 percent), primarily in those receiving flucloxacillin or <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">cloxacillin</a>, leading to early termination of the trial [<a href="#rid94">94</a>]. This finding is in keeping with other studies describing increased nephrotoxicity risk in the setting of coadministration of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> with hydrophobic beta-lactams (including <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>); the potential for nephrotoxicity appears to be lower with hydrophilic beta-lactams (<a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, most cephalosporins) [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/484.html" rel="external">"Vancomycin: Parenteral dosing, monitoring, and adverse effects in adults", section on 'Acute kidney injury'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional regimens</strong> – Potential combination regimens for which data are limited include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> plus <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> [<a href="#rid95">95</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> plus TMP-SMX [<a href="#rid96">96</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">Ceftaroline</a> plus TMP-SMX [<a href="#rid97">97</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimens associated with adverse effects</strong> – Combination regimens associated with adverse effects include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> plus <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> – Associated with an increased risk of nephrotoxicity [<a href="#rid98">98</a>] </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> plus <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> – Associated with hepatotoxicity, drug interactions, and emergence of rifampin resistance [<a href="#rid99">99,100</a>].</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> plus a hydrophobic beta-lactam (such as <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, flucloxacillin, or <a class="drug drug_general" data-topicid="9288" href="/z/d/drug information/9288.html" rel="external">cloxacillin</a>) [<a href="#rid20">20,94</a>]</p><p></p><p class="headingAnchor" id="H703148598"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110550.html" rel="external">"Society guideline links: Management of <i>Staphylococcus aureus</i> infection"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic susceptibility data</strong> − Data regarding the impact of antibiotic susceptibility on clinical response to treatment are conflicting, and other factors (apart from minimum inhibitory concentration) may influence clinical outcome. For these reasons, clinical factors (including symptomatic improvement and timeframe for clearance of bacteremia) are the most important indicators of response to antimicrobial therapy. (See <a class="local">'Interpreting antibiotic susceptibility data'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> − Initial treatment of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) bacteremia consists of monotherapy with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>; <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> is an acceptable alternative agent. (See <a class="local">'Initial treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tailored treatment</strong> − Following initiation of antibiotic treatment for MRSA bacteremia, blood cultures should be repeated to document clearance of bacteremia. Failure to clear bacteremia within 48 to 72 hours after initiation of therapy should prompt further evaluation. (See <a class="local">'Tailor treatment to clinical circumstances'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Favorable initial response</strong> − For patients with favorable clinical response to initial treatment (clearance of bacteremia within 48 to 72 hours), we continue treatment with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> monotherapy  (<a class="graphic graphic_table graphicRef114038" href="/z/d/graphic/114038.html" rel="external">table 1</a>). (See <a class="local">'Favorable response to initial treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unfavorable initial response</strong> − Patients with unfavorable clinical response to initial treatment (persistent bacteremia beyond 48 to 72 hours, persistent fever and lack of clinical improvement) warrant further evaluation for occult focus of infection that may require drainage, guided by clinical history and physical examination. In addition, antibiotic susceptibility results (on the original isolate as well as the breakthrough isolate) should be reviewed carefully for susceptibility to <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> as well as alternative agents. (See <a class="local">'Unfavorable response to initial treatment'</a> above.)</p><p></p><p class="bulletIndent2">For patients with persistent bacteremia (beyond 48 to 72 hours) in the absence of a removable focus of infection, we modify the antibiotic regimen:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with no clear source of bacteremia and increased risk for poor outcome (including critical illness, age &gt;65 years, renal disease, vertebral spine infection, injection drug use, and/or prior <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> therapy), we suggest switching to combination therapy with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> plus <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">ceftaroline</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), if supported by susceptibility data. We continue combination therapy until bacteremia has cleared with resolution of fever and clinical improvement, then complete treatment with daptomycin monotherapy.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a clear source of bacteremia (such as skin/soft tissue infection) in the absence of the above risk factors, we suggest switching from <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> monotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, daptomycin should not be used for patients with bacteremia attributable to a pneumonia source; this is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Methicillin-resistant S. aureus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> − The duration of treatment is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults", section on 'Completing antibiotic therapy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA 2013.</li><li><a class="nounderline abstract_t">Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.</a></li><li><a class="nounderline abstract_t">Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.</a></li><li><a class="nounderline abstract_t">Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333.</a></li><li><a class="nounderline abstract_t">Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193.</a></li><li><a class="nounderline abstract_t">van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755.</a></li><li><a class="nounderline abstract_t">Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340.</a></li><li><a class="nounderline abstract_t">Cervera C, Castañeda X, de la Maria CG, et al. Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis 2014; 58:1668.</a></li><li><a class="nounderline abstract_t">Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA 2014; 312:1552.</a></li><li><a class="nounderline abstract_t">Lalueza A, Chaves F, San Juan R, et al. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J Infect Dis 2010; 201:311.</a></li><li><a class="nounderline abstract_t">Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48:997.</a></li><li><a class="nounderline abstract_t">Baxi SM, Clemenzi-Allen A, Gahbauer A, et al. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2016; 60:5276.</a></li><li><a class="nounderline abstract_t">Moise PA, Culshaw DL, Wong-Beringer A, et al. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC &gt;1 mg/L: A Multicenter Evaluation. Clin Ther 2016; 38:16.</a></li><li><a class="nounderline abstract_t">Røder BL, Wandall DA, Frimodt-Møller N, et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159:462.</a></li><li><a class="nounderline abstract_t">Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010; 51 Suppl 2:S183.</a></li><li><a class="nounderline abstract_t">Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis 2014; 59:1455.</a></li><li><a class="nounderline abstract_t">Minejima E, Mai N, Bui N, et al. Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis 2020; 70:566.</a></li><li><a class="nounderline abstract_t">Kuehl R, Morata L, Boeing C, et al. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis 2020; 20:1409.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Rose W, Fantl M, Geriak M, et al. Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients? Clin Infect Dis 2021; 73:2353.</a></li><li><a class="nounderline abstract_t">Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; :CD007022.</a></li><li><a class="nounderline abstract_t">Holland TL, Bayer AS, Fowler VG. Persistent Methicilin-Resistant Staphylococcus aureus Bacteremia: Resetting the Clock for Optimal Management. Clin Infect Dis 2022; 75:1668.</a></li><li><a class="nounderline abstract_t">Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208.</a></li><li><a class="nounderline abstract_t">Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002; 186:661.</a></li><li><a class="nounderline abstract_t">Song JH, Hiramatsu K, Suh JY, et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004; 48:4926.</a></li><li><a class="nounderline abstract_t">Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.</a></li><li><a class="nounderline abstract_t">Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43:e42.</a></li><li><a class="nounderline abstract_t">Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother 2016; 71:576.</a></li><li><a class="nounderline abstract_t">van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30:603.</a></li><li><a class="nounderline abstract_t">van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 2012; 25:362.</a></li><li><a class="nounderline abstract_t">LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4665.</a></li><li><a class="nounderline abstract_t">Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227.</a></li><li><a class="nounderline abstract_t">Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190.</a></li><li><a class="nounderline abstract_t">Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192.</a></li><li><a class="nounderline abstract_t">Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731.</a></li><li><a class="nounderline abstract_t">Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45:601.</a></li><li><a class="nounderline abstract_t">Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 2013; 26:759.</a></li><li><a class="nounderline abstract_t">Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57:1568.</a></li><li><a class="nounderline abstract_t">Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177.</a></li><li><a class="nounderline abstract_t">Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.</a></li><li><a class="nounderline abstract_t">Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655.</a></li><li><a class="nounderline abstract_t">Claeys KC, Zasowski EJ, Casapao AM, et al. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. Antimicrob Agents Chemother 2016; 60:5841.</a></li><li><a class="nounderline abstract_t">Schweizer ML, Richardson K, Vaughan Sarrazin MS, et al. Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections. Clin Infect Dis 2021; 72:S68.</a></li><li><a class="nounderline abstract_t">Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37:209.</a></li><li><a class="nounderline abstract_t">Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005; 55 Suppl 2:ii5.</a></li><li><a class="nounderline abstract_t">Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57:589.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm (Accessed on October 01, 2013).</li><li><a class="nounderline abstract_t">Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.</a></li><li><a class="nounderline abstract_t">Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1963.</a></li><li><a class="nounderline abstract_t">Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11:834.</a></li><li><a class="nounderline abstract_t">Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015; 350:h2219.</a></li><li><a class="nounderline abstract_t">Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011; 52:1156.</a></li><li><a class="nounderline abstract_t">Sader HS, Flamm RK, Jones RN. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob Agents Chemother 2013; 57:3178.</a></li><li><a class="nounderline abstract_t">Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 2013; 42:450.</a></li><li><a class="nounderline abstract_t">Vazquez JA, Maggiore CR, Cole P, et al. Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia. Infect Dis Clin Pract (Baltim Md) 2015; 23:39.</a></li><li><a class="nounderline abstract_t">Paladino JA, Jacobs DM, Shields RK, et al. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents 2014; 44:557.</a></li><li><a class="nounderline abstract_t">Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review. Open Forum Infect Dis 2017; 4:ofx084.</a></li><li><a class="nounderline abstract_t">Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection. Open Forum Infect Dis 2022; 9:ofab606.</a></li><li><a class="nounderline abstract_t">Destache CJ, Guervil DJ, Kaye KS. Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience. Int J Antimicrob Agents 2019; 53:644.</a></li><li><a class="nounderline abstract_t">Furtek KJ, Kubiak DW, Barra M, et al. High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother 2016; 71:2010.</a></li><li><a class="nounderline abstract_t">Martin TCS, Chow S, Johns ST, Mehta SR. Ceftaroline-associated Encephalopathy in Patients With Severe Renal Impairment. Clin Infect Dis 2020; 70:2002.</a></li><li><a class="nounderline abstract_t">Holland TL, Cosgrove SE, Doernberg SB, et al. Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. N Engl J Med 2023; 389:1390.</a></li><li><a class="nounderline abstract_t">Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3602.</a></li><li><a class="nounderline abstract_t">King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004; 53:797.</a></li><li><a class="nounderline abstract_t">Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:1127.</a></li><li><a class="nounderline abstract_t">Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009; 49:1908.</a></li><li><a class="nounderline abstract_t">Karlowsky JA, Nichol K, Zhanel GG. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance. Clin Infect Dis 2015; 61 Suppl 2:S58.</a></li><li><a class="nounderline abstract_t">Stryjewski ME, Lentnek A, O'Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis 2014; 14:289.</a></li><li><a class="nounderline abstract_t">Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna. Clin Infect Dis 2018; 67:795.</a></li><li><a class="nounderline abstract_t">Bryson-Cahn C, Beieler AM, Chan JD, et al. Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population. Open Forum Infect Dis 2019; 6:ofz028.</a></li><li><a class="nounderline abstract_t">Gonzalez P, Rappo U, McGregor J, et al. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry. Open Forum Infect Dis 2020; 7:S140.</a></li><li><a class="nounderline abstract_t">Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.</a></li><li><a class="nounderline abstract_t">Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.</a></li><li><a class="nounderline abstract_t">Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732.</a></li><li><a class="nounderline abstract_t">Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006; 42:729.</a></li><li><a class="nounderline abstract_t">Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202.</a></li><li><a class="nounderline abstract_t">Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.</a></li><li><a class="nounderline abstract_t">Mendes RE, Deshpande LM, Castanheira M, et al. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 2008; 52:2244.</a></li><li><a class="nounderline abstract_t">Sánchez García M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260.</a></li><li><a class="nounderline abstract_t">Bonilla H, Huband MD, Seidel J, et al. Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. Clin Infect Dis 2010; 51:796.</a></li><li><a class="nounderline abstract_t">Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.</a></li><li><a class="nounderline abstract_t">Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155.</a></li><li><a class="nounderline abstract_t">Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113.</a></li><li><a class="nounderline abstract_t">Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578.</a></li><li><a class="nounderline abstract_t">Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180.</a></li><li><a class="nounderline abstract_t">Álvarez A, Fernández L, Gutiérrez D, et al. Methicillin-Resistant Staphylococcus aureus in Hospitals: Latest Trends and Treatments Based on Bacteriophages. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Fowler VG Jr, Das AF, Lipka-Diamond J, et al. Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. J Clin Invest 2020; 130:3750.</a></li><li><a class="nounderline abstract_t">McCreary EK, Kullar R, Geriak M, et al. Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. Open Forum Infect Dis 2020; 7:ofz538.</a></li><li><a class="nounderline abstract_t">Geriak M, Haddad F, Rizvi K, et al. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Jorgensen SCJ, Zasowski EJ, Trinh TD, et al. Daptomycin Plus β-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. Clin Infect Dis 2020; 71:1.</a></li><li><a class="nounderline abstract_t">Truong J, Veillette JJ, Forland SC. Outcomes of Vancomycin plus a β-Lactam versus Vancomycin Only for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Casapao AM, Jacobs DM, Bowers DR, et al. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis. Pharmacotherapy 2017; 37:1347.</a></li><li><a class="nounderline abstract_t">Kufel WD, Parsels KA, Blaine BE, et al. Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia. Pharmacotherapy 2023; 43:15.</a></li><li><a class="nounderline abstract_t">Tong SYC, Lye DC, Yahav D, et al. Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. JAMA 2020; 323:527.</a></li><li><a class="nounderline abstract_t">Miró JM, Entenza JM, Del Río A, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012; 56:4511.</a></li><li><a class="nounderline abstract_t">Claeys KC, Smith JR, Casapao AM, et al. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 2015; 59:1969.</a></li><li><a class="nounderline abstract_t">Fabre V, Ferrada M, Buckel WR, et al. Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis. Open Forum Infect Dis 2014; 1:ofu046.</a></li><li><a class="nounderline abstract_t">Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.</a></li><li><a class="nounderline abstract_t">Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674.</a></li><li><a class="nounderline abstract_t">Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2463.</a></li></ol></div><div id="topicVersionRevision">Topic 3164 Version 82.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184410" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591266" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14530782" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171250" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302374" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21742831" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647021" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25321910" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20034343" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19260820" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27324762" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26585355" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC&gt;1 mg/L: A Multicenter Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074954" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20731576" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Serious infections caused by methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25048852" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30949675" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32763194" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33993226" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination, and For Which Patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20556772" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Teicoplanin versus vancomycin for proven or suspected infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35535790" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Persistent Methicilin-Resistant Staphylococcus aureus Bacteremia: Resetting the Clock for Optimal Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407040" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195353" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561884" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516396" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886141" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565015" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : When sepsis persists: a review of MRSA bacteraemia salvage therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21191627" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491776" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predictors of mortality in Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561842" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2393284" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17173215" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17984229" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17664322" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17682996" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092854" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A current perspective on daptomycin for the clinical microbiologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24046298" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19500039" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914701" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455939" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27431221" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512521" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparative Effectiveness of Switching to Daptomycin Versus Remaining on Vancomycin Among Patients With Methicillin-resistant Staphylococcus aureus (MRSA) Bloodstream Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8707731" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The comparative efficacy and safety of teicoplanin and vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750036" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety and efficacy of glycopeptide antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507559" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507559" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22467668" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Excess deaths associated with tigecycline after approval based on noninferiority trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21685488" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy and safety of tigecycline: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784708" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25977146" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21467022" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23629712" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993067" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25574117" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Ceftaroline Fosamil for the Treatment of Staphylococcus aureus Bacteremia Secondary to Acute Bacterial Skin and Skin Structure Infections or Community-Acquired Bacterial Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25282169" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28702467" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35146040" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30711613" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27076105" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High incidence of neutropenia in patients with prolonged ceftaroline exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504321" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Ceftaroline-associated Encephalopathy in Patients With Severe Renal Impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37754204" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576125" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : In vitro activity of TD-6424 against Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028667" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728913" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911938" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Telavancin: a novel lipoglycopeptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26316559" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24884578" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29659732" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30838225" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529096" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Linezolid: the first oxazolidinone antimicrobial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917519" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236949" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16447124" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17191165" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015695" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391032" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530779" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20726771" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16323094" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16982292" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909253" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16652315" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Serotonin toxicity associated with the use of linezolid: a review of postmarketing data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16779744" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Linezolid and serotonergic drug interactions: a retrospective survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31578263" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Methicillin-Resistant Staphylococcus aureus in Hospitals: Latest Trends and Treatments Based on Bacteriophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271718" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31938716" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30858203" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31404468" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Daptomycin Plusβ-Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133561" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Outcomes of Vancomycin plus aβ-Lactam versus Vancomycin Only for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28949410" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Early Administration of Adjuvantβ-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36371648" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32044943" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcalβ-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22644033" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605354" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25734118" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207079" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929035" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474578" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
